25
June 2024
Hellenic Dynamics
plc
("Hellenic Dynamics" or the
"Company")
Directorate
Changes
London, 25 June 2024: Hellenic
Dynamics Plc (LSE: HELD), a medical cannabis cultivator with a
dedicated focus on producing tetrahydrocannabinol ("THC") dominant
strains of medical cannabis flowers for the fast growing global
medical cannabis markets, announces that
Sir Anthony Joliffe, Non-Executive Chairman of the Company, has
stepped down from the Board of Directors with immediate effect due
to age.
The Company has already begun the
process of finding a suitable replacement non-executive
chairman.
Davinder Rai, Chief Executive
Officer of the Company said that "I would like to extend my deepest gratitude
to Sir Anthony for his tenure with the Company and wish him the
very best in the future. As Hellenic moves into the next phase of
its growth stage, the Board of Directors is looking to its existing
relationships with envisioned partners, among other strategic
opportunities, for a replacement for the position of non-executive
chairperson".
The
Directors of the Company take responsibility for this
announcement.
Enquires:
Hellenic Dynamics plc
|
+44 (0)20 3818 7850
|
Davinder Rai
|
davinder@hellenicdynamics.com
|
|
|
Cairn Financial Advisers LLP
|
+44 (0)20 7213 0880
|
Emily Staples / Jo Turner
|
|
|
|
Peterhouse Capital
|
+44 (0)20 7469 0930
|
Lucy Williams / Charles
Goodfellow
|
|
About Hellenic Dynamics plc
Founded in 2019, Hellenic Dynamics is specifically focused on
the cultivation and supply of THC ("tetrahydrocannabinol") -
dominant strains of medical cannabis flowers, destined for the
growing global medical cannabis markets. Hellenic Dynamics' core
strategy is to develop and operate its 40,000 square metre active
cultivation licence from its 195,506 square metre facility located
near Thessaloniki in Northern Greece. In full production,
Hellenic Dynamics is capable of producing over 54,000 kg of dried
flowers per annum.
Hellenic Dynamics will take advantage of its relatively low
cost base resulting from a comparatively low cost of power,
having its own running water supply and the labour rates for
skilled and semi-skilled labour in Northern Greece.
26 European countries now allow medical cannabis via prescription
and the European cannabis market is expected to reach €17.39
billion per annum by 2028. Sales of Hellenic Dynamics'
dried THC-dominant cannabis flowers and extracts are initially
intended for export into Europe, in addition to other international
markets and domestically in Greece.
As the first medical cannabis
cultivator to obtain a listing on the main market for listed
securities of the London Stock Exchange, Hellenic is significantly
different to the number of CBD (Cannabidiol) related companies that
have appeared over the recent years. Hellenic Dynamics
cultivates THC-dominant medical cannabis flowers. THC-dominant
medical cannabis products are only available via a medical
prescription. Medicinal cannabis has been
approved for use both in the United Kingdom and Germany, plus 24
other European countries, for conditions including but not limited
to chronic pain, intractable
chemotherapy-related nausea, anxiety, insomnia,
Tourette's syndrome, substance use disorder, multiple
sclerosis, IBS, spinal cord treatment, lack of appetite due to
HIV/AIDS, cachexia, anorexia and glaucoma.
For further information please visit our
website www.hellenicdynamics.com
Caution regarding forward looking
statements
Certain statements in this
announcement, are, or may be deemed to be, forward looking
statements. Forward looking statements are identified by their use
of terms and phrases such as ''believe'', ''could'', "should"
''envisage'', ''estimate'', ''intend'', ''may'', ''plan'',
''potentially'', "expect", ''will'' or the negative of those,
variations or comparable expressions, including references to
assumptions. These forward-looking statements are not based on
historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of
operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof),
competitive advantages, business prospects and opportunities. Such
forward looking statements reflect the Directors' current beliefs
and assumptions and are based on information currently available to
the Directors.